Entering text into the input field will update the search result below

Healthcare Distribution Market: Growth In The Biosimilars Market And Increasing Uptake Of Biopharmaceuticals

Sep. 02, 2020 12:49 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Healthcare Distribution Market

The growth of this market is primarily driven by the rising incidence of chronic diseases, growing importance of generics, rising adoption of track & trace solutions, and the growth of the medical device industry.

Healthcare Distribution Market by Type (Pharmaceutical (Brand-name, Generic, OTC, Vitamins), Medical Device, Biopharmaceutical (Vaccines, Monoclonal Antibodies)), End User (Retail Pharmacies, Hospital Pharmacies).

In addition, emerging markets such as China and India, growth in the biosimilars market, increasing specialty drug dispensing, and increasing uptake of biopharmaceuticals are expected to offer potential growth opportunities to market players in the coming years. However, the increasing pricing pressure on market players is a major factor that is expected to impact market growth in the coming years.

According MarketsandMarkets, a new market research report – [132 Pages Report] The healthcare distribution market is projected to reach USD 1,048.4 billion by 2024 from USD 765.4 billion in 2019, at a CAGR of 6.5%.

Download PDF Brochure: Healthcare Distribution Market

Healthcare distribution market is segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services.

In 2018, the pharmaceutical product distribution services segment accounted for the largest share of the market majorly due to the increasing production of pharmaceutical formulations, rising pharmaceutical R&D expenditure, outsourcing of pharmaceutical manufacturing to Asian countries, and the establishment of new manufacturing facilitates by global pharmaceutical giants in newer geographies.

Retail pharmacies, hospital pharmacies, and other end users. The retail pharmacies segment accounted for the largest share of the market in 2018. These pharmacies deal with a large volume of prescriptions on a daily basis. Moreover, in the US and other developed countries, the implementation of programs to ensure affordable healthcare for citizens has significantly increased the volume of prescriptions in retail pharmacies.

North America dominated the healthcare distribution market in 2018. However, the APAC market is estimated to grow at the highest CAGR during the forecast period owing to the growing regulatory requirements in the healthcare industries of several APAC countries to maintain compliance with good manufacturing and distribution practices and the rising number of pharmaceutical and biotechnology companies in this region.

China and India are the fastest-growing markets in this region majorly due to the expanding pharmaceutical industries in these countries and the implementation of stringent regulations to enhance the quality and reliability of pharmaceutical drugs.

Request for Sample Pages: Healthcare Distribution Market

Key Players

Prominent players operating in the healthcare distribution market are McKesson Corporation (US), AmerisourceBergen Corporation (US), Cardinal Health, Inc. (US), Owens & Minor, Inc. (US), Morris and Dickson Co., LLC (US), KeySource Medical, Inc. (US), Rochester Drug Cooperative, Inc. (US), Henry Schein Inc. (US), Smith Drug Company (US), FFF Enterprises (US), Patterson Companies Inc. (US), Mutual Drug (US), Shanghai Pharmaceutical Group Co., Ltd. (CHINA), Medline Industries (US), PHOENIX Group (Germany), and CuraScript SD (US).

Read More: https://www.marketsandmarkets.com/Market-Reports/healthcare-distribution-market-129613751.html

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.